1	Safety and immunogenicity following co-administration of Yellow fever
2	vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines:
3	Results from an open label, non-randomized clinical trial
4	
5	John Tyler Sandberg ¹ , Marie Löfling ¹ , Renata Varnaitė ¹ , Johanna Emgård ¹ , Nabil Al-Tawil ² ,
6	Lars Lindquist ³ , Sara Gredmark-Russ ^{1,3} , Jonas Klingström ¹ , Karin Loré ⁴ , Kim Blom ^{1*} , Hans-
7	Gustaf Ljunggren ^{1*#}
8	
9 10 11	1. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
12 13	2. Karolinska Trial Alliance, Karolinska University Hospital, Stockholm, Sweden
15 14 15	3. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
16 17 18	4. Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
19	*Corresponding author: hans-gustaf.ljunggren@ki.se
20	
21	*Shared senior author (alphabetic order)
22	
23	Short title: Safety and immunogenicity following co-administration of flavivirus vaccines
24	

25 Funding

- 26 This work was supported by the Swedish Research Council (2015-02499, 2020-01365; HGL),
- 27 the Swedish Foundation for Strategic Research (SB12-0003; HGL), Region Stockholm (CIMED
- 28 2020-2022; HGL and KB), Karolinska Institutet (HGL), and a KID PhD student funding grant
- 29 from Karolinska Institutet (for JTS; HGL).
- 30

31 URLs to sponsors' websites

- 32 <u>https://ki.se/en/medh/hans-gustaf-ljunggren-group-immune-responses-to-human-virus-</u>
- 33 <u>infections-and-cancer</u>
- 34

35 Competing interest

- 36 The authors declare no competing interest
- 37
- 38
- 39

40 Abbreviations

41	AE	adverse event
42	Ab	antibody
43	ED50	50% effective dose
44	ELISA	enzyme linked immunosorbent assay
45	JEV	japanese encephalitis virus
46	nAb	neutralizing antibody
47	PCR	polymerase chain reaction
48	RFFIT	rapid fluorescent focus inhibition test
49	SAE	serious adverse event
50	TBEV	tick-borne encephalitis virus
51	YFV	yellow fever virus

52 Author summary

53

54 Why was this study done?

- Flavivirus infections pose a significant global health burden, underscoring the need for
- 56 the development of safe and efficient vaccination strategies
- Co-administration of different flavivirus vaccines saves time and visits to health care
- 58 units and vaccine clinics. It serves to provide protection against multiple pathogens in a
- 59 shorter time-span, both for individuals living in or travelling to endemic areas
- Safety and immunogenicity-related responses have not been appropriately evaluated upon
- 61 co-administration of many vaccines including currently used flavivirus vaccines, such as
- 62 Yellow fever virus (YFV), Tick-borne encephalitis virus (TBEV), and Japanese
- 63 encephalitis virus (JE) virus vaccines
- Because of this, we performed an open label, non-randomized clinical trial studying the
 safety and immunogenicity following co-administration of YFV vaccine with TBEV and
 JEV vaccines
- 67
- 68 What did the researchers find?
- Adverse events, neutralizing antibodies (nAbs) and other related immunological
 parameters were not adversely affected by concomitant delivery of the vaccines
- Concomitant vaccination in the same versus different upper arms of study participants did
 not significantly affect safety or immunogenicity outcomes
- 73
- 74 What do these findings mean?

75	•	Co-administration of YFV vaccine and TBEV or JEV vaccines is feasible without
76		increased risk of adverse events or reduced development of nAbs against the respective
77		viruses. Furthermore, the vaccines can safely be delivered in the same upper arm without
78		negative outcome

79 Abstract

80 Background

81 Flavivirus infections pose a significant global health burden underscoring the need for the 82 development of safe and efficient vaccination strategies. Available flavivirus vaccines are from 83 time to time concomitantly delivered to individuals in need. Co-administration of different vaccines saves time and visits to health care units and vaccine clinics. It serves to provide 84 85 protection against multiple pathogens in a shorter time-span, both for individuals living in, or 86 travelling to, endemic areas. However, safety and immunogenicity-related responses have not 87 been appropriately evaluated upon concomitant delivery of these vaccines. Therefore, we 88 performed an open label, non-randomized clinical trial studying the safety and immunogenicity following concomitant delivery of the Yellow fever virus (YFV) vaccine with Tick-borne 89 90 encephalitis virus (TBEV) and Japanese encephalitis virus (JE) virus vaccines.

91

92 Methods and findings

93 Following screening, healthy study subjects were enrolled into different cohorts receiving either 94 TBEV and YFV vaccines, JEV and YFV vaccines, or in control groups receiving only the 95 TBEV, JEV, or YFV vaccine. Concomitant delivery was given in the same or different upper 96 arms for comparison in the co-vaccination cohorts. Adverse effects were recorded throughout the 97 study period and blood samples were taken before and at multiple time-points following 98 vaccination to evaluate immunological responses to the vaccines. Adverse events were 99 predominantly mild in the study groups. Four serious adverse events (SAE) were reported 100 throughout the trial, none of them deemed related to vaccination. The development of 101 neutralizing antibodies (nAbs) against TBEV, JEV, or YFV was not affected by the concomitant

102	vaccination strategy. Concomitant vaccination in the same or different upper arms did not
103	significantly affect safety or immunogenicity-related outcomes. Exploratory studies on
104	immunological effects were additionally performed and included studies of lymphocyte
105	activation, correlates associated with germinal center activation, and plasmablast expansion.
106	
107	Conclusions
108	Inactivated TBEV or JEV vaccines can be co-administered with the live attenuated YFV vaccine
109	without an increased risk of adverse events and without reduced development of nAbs to the
110	respective viruses. The vaccines can be delivered in the same upper arm without negative
111	outcome.
112	
113	Trial registration
114	Eudra CT 2017-002137-32

116 Introduction

117 Yellow fever virus (YFV), Tick-borne encephalitis virus (TBEV), and Japanese encephalitis 118 virus (JEV) all belong to the *Flavivirus* genus of the *Flaviviridae* family of viruses. These 119 viruses pose major global health challenges, both for inhabitants in affected areas (around 1/3 of 120 the world's population) as well as for travelers to these areas [1-5]. Infection with these viruses 121 is associated with significant morbidities, hospitalization costs, sick leave-associated costs, and 122 loss of productivity as well as over 100,000 of fatal outcomes per year [2,4,6–9]. No specific 123 treatment or antiviral drugs for these diseases exists, though development of antiviral drug 124 candidates has been initiated [10–14]. There are, however, approved vaccines against these 125 flaviviruses [15–17]. These vaccines are frequently used to prevent disease among inhabitants 126 living in endemic areas and for travelers visiting these areas.

The vaccine regimen and outcome of vaccinations against YFV, TBEV, and JEV
infections differ significantly. After a single dose, the live attenuated YFV vaccine provides at
least 10 years, and possibly life-long, immunity [18–20]. In contrast, the current inactivated
TBEV and JEV vaccines licensed in Europe require multiple doses for primary immunization
and regular booster doses to maintain immunity [15,16,20,21].

Safe and efficient vaccine administration strategies are of significant importance [22].
Rigorous clinical trials have assessed the safety and immunogenicity of most currently approved
vaccines. However, data are limited with respect to interactions of many vaccines, including the
YFV vaccine, with other vaccines including all currently available flavivirus vaccines [23–32].
Published studies are limited to a few reports on concomitant vaccination of the YFV vaccine
with other vaccines including smallpox, Bacillus Calmett-Guérin (BCG), hepatitis B or cholera
vaccines [33–35].

139 Endemic flaviviruses overlap in some parts of the world, affecting local inhabitants as 140 well as travelers with needs for protection. Simultaneous vaccination with different vaccines 141 saves time and visits to health care units and vaccine clinics. It provides protection against 142 multiple pathogens in a shorter time-span when an individual may be vulnerable to infection. As 143 mentioned, there is also often a need for individuals to rapidly protect themselves from 144 flaviviruses prior to travelling to endemic areas. This has been further emphasized more recently 145 given that present flavivirus endemic areas are currently increasing, likely due to changes in 146 climate change and other factors [1,36–38]. Together, this has called for more systematic 147 evaluations of the effects of concomitant delivery of flavivirus vaccines, particularly with respect 148 to safety and immunogenicity.

149 To this end, we carried out an open label, non-randomized clinical trial assessing the 150 safety and immunogenicity of concomitant vaccination with different commonly used flavivirus 151 vaccines. The clinical trial included healthy adult volunteers who were concomitantly vaccinated with TBEV and YFV vaccines, JEV and YFV vaccines, or with only one of the three respective 152 153 vaccines. Half of the concomitantly vaccinated study participants received both vaccines in the 154 same upper arm while the other half received the vaccines in different upper arms. Blood 155 samples were taken before and at multiple time-points following vaccinations. Safety and 156 immunological responses including nAbs were evaluated. Collectively, the study provides safety 157 and immunogenicity outcomes following concomitant vaccination with different types of 158 flavivirus vaccines.

159 Methods

160 Ethical and regulatory approval

161 The study was approved by the Stockholm Local Regional Ethical Committee (2017/1433-31/1)

and the Swedish Medical Products Agency (5.1-2017-52376). It is registered in the European

database (Eudra CT 2017-002137-32). All study volunteers signed informed consent documents

in line with the ethical approval and clinical trial protocol.

165

166 Study design and participants

167 An open label, non-randomized academic (non-Pharma sponsored) clinical trial was conducted 168 in order to assess safety and immunological responses of concomitant vaccination with three 169 currently licensed flavivirus vaccines. The trial was conducted at the Karolinska University 170 Hospital, Stockholm, Sweden. An independent data monitoring process was setup by the 171 Karolinska Trial Alliance (KTA) support organization (KTA Support) in order to review safety 172 data and the progress of the study according to the clinical trial protocol. The monitoring process 173 also included review of the trial's conductance in accordance with principles of good clinical 174 practice (ICH-GCP)[39]. Volunteer recruitment, medical examination, vaccination, and 175 peripheral blood sampling were handled by the KTA Phase I unit at the Karolinska University 176 Hospital. Recording of informed consent, adherence to set inclusion and exclusions criteria 177 including previous vaccinations, age, gender, and a standardized medical examination was 178 performed (including temperature, pulse, blood pressure, and pregnancy test) prior to inclusion 179 in the study. Inclusion criteria allowed volunteers between 18 to 55 years of age who wanted

180	protection to YFV, TBEV, and/or JEV, and who were willing to provide written consent to enter
181	the study. Exclusion criteria included, but were not limited to, previous known infection with or
182	vaccination against YFV, TBEV, and JEV, allergy to eggs, poultry or fructose,
183	immunocompromising diseases, autoimmune diseases, medication for cancer or
184	immunosuppression, HIV or HCV infection, fever within one week of scheduled vaccination,
185	pregnancy, hemophilia, and/or involvement in other medical studies. All study volunteers were
186	properly insured with respect to vaccination and blood sampling risks. Study participants were
187	entitled to leave the study at any time without reason. Further details with respect to exclusion
188	criteria and specific criteria for termination of the study are outlined in the clinical trial protocol.

189

190 Vaccines

The following vaccines were used in the trial: Stamaril[®] (Sanofi), live, attenuated YFV 17D 191 192 strain produced in pathogen-free chick embryo cells, 0.5 ml, not less than 1,000 IU. The vaccine 193 was provided in freeze dried powder form and reconstituted with provided saline solution and was administered subcutaneously. IXIARO® (Valneva), inactivated, alum-adjuvanted, Vero cell-194 195 derived vaccine based on JEV strain SA₁₄-14-2, 0.5 ml. The vaccine was provided in the form of pre-filled syringe attached without needle containing an 0.5 mL dose and was administered 196 intramuscularly according to the manufacturer's label. FSME IMMUN[®] (Pfizer), inactivated, 197 198 alum-adjuvanted, chick embryo cell derived vaccine based on the Neudörfl strain, 0.5 ml. The 199 vaccine was provided as a pre-filled syringe attached without needle containing a 0.5 mL dose 200 and was administered intramuscularly according to the manufacturer's label. All vaccines were 201 obtained from Apoteket AB, Karolinska University Hospital, Solna, Sweden and kept at the 202 Phase-1 unit, KTA, Karolinska University Hospital, at its Huddinge site.

203

204 Study design and cohorts

205 The study was initially designed to include a total of 140 healthy volunteers. Forty study 206 participants were to receive both TBEV and YFV vaccines (cohort A). Twenty of these 207 participants were to receive the vaccines in different upper arms (sub-cohort A1) and the other 208 20 in the same upper arm (sub-cohort A2). The next 40 study participants were to receive both 209 JEV and YFV vaccines (cohort B). Similarly, 20 of these participants were to receive the 210 vaccines in different upper arms (sub-cohort B1) and the other 20 in the same upper arm (sub-211 cohort B2). The remaining three cohorts of 20 study participants per cohort, were aimed to serve 212 as study controls and were to receive either, the TBEV vaccine (cohort C), JEV vaccine (cohort 213 D), or YFV vaccine (cohort E). 214 Upon initiation of the clinical trial, a total of 161 healthy volunteers were screened for 215 enrollment (Fig 1A). 145 study participants were found eligible for entering the study and 216 assigned to it. Of these, 43 participants were assigned to cohort A (A1, 23 participants; A2, 20 217 participants), 42 participants to cohort B (B1, 21 participants; B2, 21 participants), and 20 218 participants each to cohorts C, D, and E. Cohort A1 had in total three study participant dropouts 219 and cohorts B1, B2, and C had one study participant dropout each, following enrollment to the 220 study. Hence, 139 study subjects in total completed the trial. A total of 13 missed visits out of 221 1,150 total planned visits occurred during the course of the trial. 222

223 **Procedures**

224 Vaccinations were given in accordance with the clinical trial protocol and good clinical practice 225 (GCP), with intervals for primary vaccinations as recommended in FASS (Pharmaceutical 226 Specialties in Sweden): FSME IMMUN, three doses 0-, 1- and 5-month intervals; IXIARO, two 227 doses, 0- and 1-month interval; Stamaril, one dose, For cohorts A1, A2, B1, B2, C, and D, blood 228 and serum were sampled before each vaccination, and then at day 7 (+/-1 day) and at day 14. 229 Blood and serum were also sampled 30 days after the last vaccination (+14 days). For cohort E, 230 blood and serum were sampled before the vaccination, and then at day 7 (+/-1 day), at day 14, at 231 day 30 (+/-2 days), day 37 (+/-1 day), day 44 (+5 days) and day 60 (+14 days). This schedule 232 led to the following approximate time allocations in terms of days for blood and serum 233 samplings: cohorts A and C, days 0 (first vaccination), 7, 14, 30 (second vaccination), 37, 44, 234 180 (third vaccination), 187, 194, and 210; cohorts B and D, days 0 (first vaccination), 7, 14, 30 235 (second vaccination), 37, 44, and 60: cohort E, days 0 (vaccination), 7, 14, 30, 37, 44, and 60 236 (Fig 1B). At each sampling time-point, 40-45 ml of venous blood from study participants was 237 collected in vacuum serum and EDTA tubes (BD). PBMCs were isolated using gradient 238 centrifugation and used for immediate analyses as well as also being cryopreserved for 239 subsequent studies. Serum tubes were allowed to stand upright for 2 hours at room temperature. 240 Serum was subsequently isolated by centrifugation at 2,000 X g for 10 minutes and stored at -241 80°C for later analysis.

243 Safety assessment

Results from physical examination, including vital signs and body temperature, pulse, and blood
pressure was recorded at each time-point for vaccination. Adverse events (AEs) following
vaccinations were recorded from each study participant at each visit and classified as mild,
moderate, or severe. Severe adverse events were, when so deemed, classified as serious adverse
events (SAEs). AEs and SAEs recorded for all study participants were deemed unlikely,
possible, or probably related to the vaccinations.

250

251 Determination of YFV RNA levels in serum

252 YFV-specific real-time PCR was used to determine the viral RNA in serum of study participants. 253 RNA was isolated from 150 µL of serum using a NucleoSpin RNA Virus Kit (Machery-Nagel). 254 One step real-time PCR was performed using TagMan Fast Virus 1-Step Master Mix (Applied 255 Biosystems), a FAM-TAMRA-labeled probe and primers (Fisher Biotechnology) according to 256 the manufacturer's instructions. The primers and probe were all specific for the highly conserved 257 NS5 gene of YFV [40] and were used at a final concentration of 800 nM and 125 nM for the 258 primers and probe, respectively. Amplifications were performed in 25 μ L reactions using a 259 OuantStudio 5 real-time PCR machine (Applied Biosystems) under the following thermal 260 cycling conditions: 5 min at 50°C, 20 s at 95°C, 45 cycles of 15 s at 95°C, followed by 1 min at 60°C. RNA from the YFV 17D was calibrated in relation to a standard curve commercially 261 262 available in the Techne qPCR test for YFV (Techne) and used for quantification. The limit of 263 detection was 20 copies per 1 mL.

264

265 Clinical chemistry

266 C-reactive protein (CRP), albumin (ALB), creatinine, bilirubin, aspartate transaminase (AST),

alanine aminotransferase (ALT), alkaline phosphatase (ALP), and gamma-glutamyltransferase

268 (GGT) were analyzed at the Karolinska University Hospital accredited clinical chemistry

laboratory at the first three time-points (days 0, 7, and 14).

270

271 Absolute cell counts

Absolute numbers of cells expressing CD45, CD3, CD4, and CD8 in peripheral blood were

273 measured using BD TrucountTM tubes (BD Biosciences) according to the manufacturer's

instructions. Briefly, 50 µL of anticoagulated blood was added to Trucount[™] tubes within three

hours after extraction and thereafter fluorescently stained for CD45, CD3, CD4, and CD8 for 15

276 minutes at RT in the dark. Samples were then fixed with 1X BD FACS lysing solution before

277 acquiring data on a BD Accuri flow cytometer (BD Biosciences).

278

279 Multiplex measurement of cytokine secretion

280 GM-CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10, TNF, IFN-α2, MIP-1β, IL-12, IL-15 and IL-18

were measured in serum, diluted 1:4, from the first four time-points (days 0, 7, 14, and 30) from

each study participant using a pre-designed 8-plex assay with a custom-designed 5 single-plex

assay Bio-Plex Pro Human Cytokine Assay (Bio-Rad), according to the manufacturer's

284 instructions.

286 Antibody analyses

Assessment of virus-specific IgG levels and neutralizing antibody titers (nAbs) against TBEV. 287 JEV and/or YFV was performed on day 0, day 30, and at the final time-point of the clinical trial 288 289 (day 210 for cohort A and cohort C, day 60 for B, D, and E). TBEV-specific IgG antibodies were 290 assessed using an anti-TBE virus ELISA "Vienna" (IgG) kit (Euroimmun) and JEV-specific IgG 291 antibodies were assessed using an anti-JEV ELISA (IgG) kit (Euroimmun) according to the 292 manufacturer's instructions. Both assays included complete virus lysates as coating antigen. 293 Antibody levels equal to, or greater than, 120 were considered seropositive for TBEV-specific 294 IgG and levels equal to, or greater than, 20 were considered seropositive of JEV-specific IgG, 295 both as determined by the ELISA kit manufacturer. TBEV-specific IgG levels >1,000 Vienna 296 units were recorded as 1,000 Vienna units and likewise, JEV-specific IgG levels ≥200 RU/ml 297 were recorded as 200 RU/ml.

298 Virus neutralization was measured by rapid fluorescent focus inhibition test (RFFIT) as 299 previously described with modifications for TBEV, JEV and YFV [41]. Briefly, serum from days 300 0, 30 and the final time-point (day 210 for cohort A and cohort C, day 60 for B, D, and E) were 301 heat-inactivated and tested in serial dilutions with fifty 50% focus-forming doses of either TBEV (93-783 strain), JEV (Nakavama strain) or YFV (Asibi strain) in flat-bottom 96-well plates. 302 303 Following a 90-minute incubation of serum and virus, 50,000 trypsinized BHK-21 cells were 304 added to each well and the plates were incubated for 24 hours. Following incubation, cells and 305 virus were discarded and then fixed in 80% acetone for 1 hour at -20° C. After fixation, virus 306 infected cells were detected by staining with optimized dilutions of mouse anti-TBEV (clone 307 1004134, Bio-Techne), mouse anti-JEV (clone 6B4A-10, Merck) or mouse anti-YFV (clone 308 2D12-A, Merck) followed by detection with Alexa Fluor 488 AffiniPure goat anti-mouse IgG

309 (H+L) (Jackson ImmunoResearch). Virus infected cells were detected using fluorescence
310 microscopy and an IRIS FluoroSpot reader (Mabtech). In each well, 20 fields were examined for
311 fluorescent foci (infected cells) and fields with one or more foci were recorded. Titers are
312 defined as 50% effective dose (ED50) and reciprocal titers of ED50 ≥5 were deemed positive.
313 Titers less than 5 showed no neutralizing capacity or less than 50% reduction.

314

315 Flow cytometry

316 Freshly isolated PBMCs were used for phenotypical analysis using the following antibodies:

317 Live/Dead cell marker Near IR (Life Sciences), anti-CD19 (clone SIJ25C1) BUV 395, anti-CD4

318 (clone SK3) BUV 737, anti-CD16 (clone 3GB) Pacific Blue, anti-CD14 (clone MoP9) AmCyan,

anti-Ki67 (clone B56) AF700 (BD Biosciences), anti-CD20 (clone 2H7) FITC, anti-CD123

320 (clone 6H6) AmCyan, anti-CD27 (clone O323) BV650, anti-CD38 (clone HIT2) BV785, anti-

321 IgD (clone IA6-2) PE-Cy7, anti-IgG (clone HP6017) PE (BioLegend), anti-CD56 (clone N901)

322 ECD, anti-CD3 (clone UCHt1) PE-Cy5 (Beckman Coulter), anti-CD8 (clone 3B5) Qdot 605

323 (Invitrogen) and anti-IgA (clone IS11-8E10) APC (Miltenyi Biotech). Cells were incubated with

 $50 \,\mu\text{L}$ of surface staining antibody mix diluted in PBS for 30 minutes at 4°C in the dark.

Following incubation, the cells were washed twice in FACS buffer (2% FCS and 2 mM EDTA in

PBS) and then fixed and permeabilized using Foxp3/Transcription Factor Staining kit

327 (eBioscience) for 30 minutes at 4°C. Cells were then washed twice in permeabilization buffer

328 (eBioscience) followed by intracellular staining. Antibodies against Ki67 and IgG in

329 permeabilization buffer were added to the cells and incubated in the dark for 30 minutes at 4°C.

330 Cells were finally washed with FACS buffer and data acquired on a BD LSR Fortessa (BD

Bioscience). Analysis of acquired data was done with FlowJo software version 10 (FlowJo Inc).

332

333 CXCL13 ELISA

Undiluted serum was thawed at room temperature and analyzed using a Quantikine Human
CXCL13/BLC/BCA-1 ELISA (R&D Systems) according to the manufacturer's instructions.
Limit of detection of the assay ranged between 7.8 and 500 pg/mL.

337

338 Statistics

339 Statistical analyses were performed using GraphPad Prism (GraphPad Software). Data sets were

340 analyzed using non-parametric Wilcoxon matched-pairs signed rank test, Kruskal-Wallis, or

341 Friedman tests. Dunn's multiple comparisons test was used to correct for multiple comparisons

342 where applicable. Handling of missing values due to missed visits (13 out of 1,150 visits) were

343 determined before analysis according to the study protocol. In line with this, missing values were

344 imputed in Figs using median values from the specific time-point in each cohort. All *p*-values

345 <0.05 were considered to be statistically significant (*p < 0.05; **p < 0.01; and ***p < 0.001).

347 **Results**

348 Study participants and vaccination schedule

140 study subjects were planned for the present clinical trial. Over the course of 17 months, 161 349 350 volunteers were screened, 145 of whom were found to be eligible for the clinical trial and 351 enrolled into one of the seven cohorts (A1, A2, B1, B2, C, D, and E). All but six study participants completed the trial, leaving the clinical trial with a final 139 study participants (Fig 352 353 1A). These 139 study participants all completed the full duration of the study and were included 354 in subsequent safety and immunogenicity assessments. Cohorts A1 and A2 (n=40) received the 355 TBEV and YFV vaccine at day 0, and subsequent TBEV vaccine doses 1 month after the first 356 dose, and at 5 months after the second dose. Cohort A1 (n=20) received TBEV and YFV 357 vaccines in different upper arms and cohort A2 (n=20) in the same upper arm. Cohorts B1 and 358 B2 (n=40) receive received the JEV and YFV vaccine at day 0, and subsequent JEV vaccine 359 dose at 1 month after the first dose. Cohort B1 (n=20) received JEV and YFV vaccines in different upper arms and cohort B2 (n=20) in the same upper arm. Cohorts C (n=19), D (n=20) 360 361 and E (n=20) received TBEV, JEV, or YFV vaccinations, respectively, following the same dose 362 schedule as described in cohorts A and B (Fig 1B). The study participants were age and sex-363 matched across the cohorts (Table 1).

	A1	A2	B1	B2	С	D	E	All cohorts
	(n=20)	(n=20)	(n=20)	(n=20)	(n=19)	(n=20)	(n=20)	(n=139)
Age (years)								
Average (SD)	31.3 (9)	28.9 (7.1)	28.3 (10.2)	27.8 (4.6)	24.4 (5.9)	26 (6.3)	29.7 (9.5)	28.1 (7.9)
Median (IQR)	29 (10.5)	25.5 (7.8)	25 (6)	27.5 (7)	23 (4)	25 (2.5)	28.5 (11.8)	26 (7)
Min, Max	18. 53	22. 46	21. 53	22. 38	20. 46	18. 47	18. 54	18. 54
Gender (%)								
Male	7 (35)	6 (30)	9 (45)	10 (50)	6 (31.6)	7 (35)	8 (40)	53 (38.1)
Female	13 (65)	14 (70)	11 (55)	10 (50)	13 (68.4)	13 (65)	12 (60)	86 (61.9)
364								

Table 1 | Cohort characteristics

365 Adverse events

69.8% of the 139 included study participants reported one or more AEs during the course of the
clinical trial (Table 2). 77.4% of all AEs across all cohorts were mild, 20.8% were moderate, and

368 1.8% were severe. 65.2% of all AEs across all cohorts were deemed unlikely related to

369 vaccination, while 11.8% were deemed possibly related to vaccination and 23.1% were deemed

370 probably related to vaccination (**Table 2**).

371

372

373

374 The most frequent AEs were common cold-like symptoms followed by redness/tenderness at the

375 injection site, headache, fever, and influenza-like symptoms. The latter four symptoms represent

376 classical reactogenicity related responses.

377 Cohorts A1, A2 and C, all of which received TBEV vaccinations, had a greater number of total

registered AEs compared to the other cohorts, ascribed to multiple (n=3) TBEV vaccinations.

379 Cohorts B1, B2, and D, all of which received JEV vaccinations, had greater number of total

380	registered AEs compared to the E cohort, concordantly ascribed to multiple (n=2) JH	ΞV
-----	---	----

381 vaccinations. Four AEs were deemed severe, all of which were determined SAEs. These SAEs

included one case with hip dysplasia in a newborn child of a study participant, one case with

383 pneumonitis, one case with depression, and one case with a fall, all four of which were

determined to be unrelated to vaccination. A full list of the cohorts' AEs is shown in STables 1

385 and **2**.

	A1	A2	B1	B2	С	D	Е	Total
	(n=20)	(n=20)	(n=20)	(n=20)	(n=19)	(n=20)	(n=20)	(n=139)
Total AE	40	51	25	19	36	31	19	221
Donors with at least one AE	18	15	12	10	15	16	11	97
Severity:								
Mild	35	35	21	12	26	26	16	171
Moderate	4	15	4	7	9	5	2	46
Severe	1	1	0	0	1	0	1	4
Related to vaccination								
Unlikely	25	36	18	8	21	20	16	144
Possible	5	3	2	8	5	1	2	26
Probable	10	12	5	3	10	10	1	51

Table 2 | Summary of registered adverse events

387 Viral RNA levels, clinical chemistry, and immunology

388 The YFV vaccine causes a mild infection, often with detectable virus in circulation. As a safety-

389 related assessment, we measured serum YFV NS5-RNA levels in all cohorts vaccinated with the

390 YFV vaccine in order to assess if concomitant vaccination had any effects on YFV viral

391 replication. Across all study cohorts, most study participants receiving the YFV vaccine had

detectable levels of YFV NS5-RNA seven days after vaccination (Fig 2A). In all but four study

393 participants, no YFV NS5-RNA was detectable at 14 days following vaccination. Overall, no

³⁸⁶

394	significant differences were observed between the study cohorts with the exception of cohort B2
395	which was found to have somewhat higher median levels of YFV NS5-RNA copies in serum
396	(Fig 2B). Based on these findings, we conclude that concomitant vaccination did not generally
397	affect YFV replication in the study participants receiving concomitant vaccination.
398	As YFV infection can lead to liver and kidney damage, we assessed common
399	inflammation as well as kidney- and liver-related clinical chemistry analytes to evaluate the
400	effects of concomitant vaccination. No significant changes were observed over time in the
401	cohorts with most clinical chemistry values lying within the normal range for healthy individuals
402	(Fig 2C). These findings suggest that TBEV or JEV vaccination together with the YFV vaccine
403	have no major systemic effects on kidney or liver organ function.
404	Further laboratory assessment included basic cellular immunological measurements
405	following concomitant vaccination. This included standardized clinical diagnostic TruCount
406	assays, in which absolute numbers of CD45 ⁺ , CD4 ⁺ , and CD8 ⁺ cells were measured (Fig 2D).
407	Increases in CD45 ⁺ and CD4 ⁺ cell numbers were, as expected, observed at day 14 after
408	vaccination in all cohorts. Similarly, CD8 ⁺ cells increased in absolute number 14 days following
409	vaccination, however, only in cohorts receiving the YFV vaccine. There were no general
410	differences in absolute cell counts at day 14 between the study cohorts when assessing overall
411	patterns compared to days 0, 7 and 30, respectively.
412	As a final laboratory measurement assessing concomitant vaccination, multiple soluble
413	cytokines and chemokines were measured in serum before and at the three first time points
414	following vaccination in all cohorts. Of these, IL-18, IL-8, TNF and MIP-1 β were at detectable
415	levels among most study participants while GM-CSF, IFN-y, IL-2, IL-4, IL-6, IL-10, IFN-a2,
416	IL-12, and IL-15 were below detection levels in the majority of study participants (S1 Fig).

417	Notable increases in TNF and IL-18 levels were observed in all cohorts receiving the YFV
418	vaccine (cohorts A1, A2, B1, B2, and E) (Fig 2E). There were no statistically significant
419	differences in TNF or IL-18 levels between these cohorts at any of the measured time-points.
420	Taken together, no marked clinical safety-related effects following concomitant
421	vaccination of the TBEV or JEV vaccines with the YFV vaccine were observed. Nor were there
422	any statistical differences observed when vaccines were administered in the same or different
423	upper arms of study participants.

424

425 Virus specific IgG levels

As part of the primary endpoint, TBEV and JEV specific IgG levels were measured before
vaccination and at days 30 (30 days after dose 1) and 210 (30 days after dose 3) for the TBEV
vaccine cohorts, and at days 30 (30 days after dose 1) and 60 (30 days after dose 2) for the JEV
vaccine cohorts.

430 Study participants from cohorts A1, A2, and C all developed IgG antibodies against 431 TBEV by the end of the trial (Fig 3A). A total of six study participants from these three cohorts 432 had pre-existing antibodies at day 0 by using the detection threshold (\geq 120 Vienna units) for 433 positive response as defined by the manufacturer. For all cohorts, a gradual increase of virus specific IgG levels was observed as assessed at day 30 and day 210 (Fig 3A). All responses were 434 435 above the positive threshold at the final time-point (Fig 3B). Cohorts A1, A2, and C did not 436 differ significantly from each other (Fig 3B). The majority of study participants from cohorts B1, 437 B2, and D developed IgG antibodies against JEV by the end of the trial (Fig 3C). A total of 18 438 study participants from these three cohorts presented with pre-existing antibodies at day 0 439 according to the manufacturer's positive threshold ($\geq 20 \text{ RU/mL}$). For all cohorts, a gradual

increase of virus specific IgG levels was observed as assessed at day 30 and day 60 (Fig 3C). At
the final time-point, no significant differences in antibody titers were observed between cohorts
B1, B2, and D (Fig 3D). Consequently, cohorts B1 and B2 did not differ significantly from each
other (Fig 3D).

444

445 Virus neutralization

446 Apart from the assessment of antigen-binding IgG responses, rapid fluorescence focus inhibition 447 tests (RFFIT) were performed to measure nAb titers against TBEV, JEV, and YFV to compare 448 the effect of concomitant vaccinations with respective single vaccination outcomes. All study 449 participants were screened at day 0 for nAbs against the three flaviviruses. Two study 450 participants had nAbs against TBEV at day 0 (one each from cohorts A1 and A2, respectively). 451 These were excluded from subsequent analyses. No study participants had preexisting nAbs 452 against JEV or YFV at day 0. Few study participants developed TBEV nAbs at day 30, however, the majority 453 454 developed positive titers by day 210 (30 days after third dose) (A1: 85%, A2: 95%, and C: 79%) 455 (Fig 3E). There were no statistically significant differences in nAb titers between cohorts A1, 456 A2, and C (Fig 3F). Similarly, there were no statistically significant differences in nAb titers 457 when cohorts A1 and A2 were compared (Fig 3F). Similar to TBEV, few study participants 458 developed JEV nAbs at day 30, however, the majority developed positive titers by day 60 (30 459 days after third dose) (B1: 85%, B2: 55%, and D: 60%) (Fig 3G). There were no statistically 460 significant differences in nAb titers between cohorts B1, B2, and D (Fig 3H). There were no 461 statistically significant differences in nAb titers when cohorts B1 and B2 were compared (Fig

462 3H). All study participants from the cohorts receiving YFV vaccination developed nAbs by day

463 60 (Fig 3I). Additionally, there were no statistically significant differences in YFV nAb titers
464 between cohorts A1, A2, B1, B2, and E (Fig 3J).

No statistical differences were observed in terms of nAb titers were observed when 465 466 concomitant vaccinated study participants had received their respective vaccine in the same 467 upper arm (2.5 cm distance according to protocol) versus in different upper arms. A trend 468 towards higher titers (mean value) of nAb was noted in the groups where vaccines were given in 469 the same upper arm (cohorts A2 and B2) versus different upper arms (cohorts A1 and B1) (Figs 470 **3F and H)**. 471 The design of the clinical trial also allowed us to divide the enrolled study subjects based 472 on gender. No statistically significant differences were observed between males and females in 473 terms of final nAb titers against TBEV, JEV, or YFV (Fig S2). Noteworthy, however, an 474 indication of an increase in females versus males in the TBEV-specific nAb titers were observed when assessing all study participants receiving the TBEV vaccine (Fig S2A, right panel). 475 In summary, concomitant TBEV or JEV vaccination with YFV vaccine did not affect the 476 development of virus-specific nAbs towards TBEV or JEV. Likewise, YFV nAb titers did not 477 differ between the cohorts, whether the YFV vaccine was administered alone or together with the 478 479 TBEV or JEV vaccines (Fig 3J).

480

481 Activation of B cells, T cells and NK cells

In addition to the virus-specific binding IgG antibody responses and nAbs we, we expanded the analyses in exploratory studies to investigate specific cellular responses following vaccination of the different cohorts. Freshly isolated PBMCs from each time-point were used to assess the effects of concomitant vaccinations on lymphocyte activation. Co-expression of CD38 and Ki67

486	in B cells, CD4 ⁺ T cells, CD8 ⁺ T cells, and NK cells (CD56 ^{dim} population of NK cells when not
487	else noted) was measured (Fig 4A). Cohorts A1, A2, B1, B2, and E (all vaccinated with the YFV
488	vaccine) exhibited increased frequencies of activated B cells, CD4 ⁺ T cells, CD8 ⁺ T cells, and
489	NK cells at day 14 following vaccination (Fig 4B-E). A trend towards earlier activation of NK
490	cells was observed in some study participants (Fig 4E), in line with previous reports [42,43]. In
491	general, vaccination with only YFV vaccine or vaccination with concomitant vaccination with
492	YFV vaccine and TBEV or JEV vaccine led to a stronger activation among these cellular subsets
493	compared to single vaccination with the TBEV or JEV virus vaccine (Fig 4B-E). No statistically
494	significant differences in lymphocyte activation were observed between cohorts A1 and A2, as
495	well as between B1 and B2 (Fig 4B-E), with the exception of a more marked CD4 ⁺ T cell
496	activation in group B2 versus group B1 (Fig 4C).

497

498 Germinal center activation and plasmablast responses

499 The observed activation of lymphocyte subsets indicates induction of innate and adaptive

500 immune responses, likely linked to the development of protective immunity (nAbs). We

501 therefore further explored parameters related to induction of humoral immunity such as germinal

502 center activity and plasmablast expansion following vaccination.

503 First, CXCL13 levels in serum were measured as a proxy to germinal center activity.

Elevated levels of serum CXCL13 were observed at days 7 and/or 14 following each vaccination

- 505 in all cohorts, with the most marked changes seen amongst vaccine cohorts receiving the YFV
- 506 vaccine (cohorts A1, A2, B1, B2, and E) (Fig 5A). Plasmablast expansion as a result of germinal
- 507 center formation was also analyzed. An increase in the number of plasmablasts was observed 14
- 508 days after vaccination in all cohorts receiving the YFV vaccine (cohorts A1, A2, B1, B2 and E)

509	(Fig 5B and C). Similar to B cell activation (Fig 4B), the concomitant vaccine cohorts (cohorts
510	A1, A2, B1, B2) had significantly higher frequencies of plasmablasts at day 14 than the single
511	TBEV and JEV vaccine cohorts (cohorts C and D). Additional deeper analyses were also
512	performed, including studies of plasmablast specific immunoglobulin expression over time (S3
513	Fig).
514	Together these findings indicated that concomitant TBEV or JEV vaccination with the
515	YFV vaccine leads to a marked germinal center activation and plasmablast expansion, likely

516 resulting to a significant extent from the YFV vaccine response.

517 **Discussion**

518 Here, we report the results of an open label, non-randomized, academic clinical trial assessing 519 the safety and immunogenicity upon concomitant vaccination with different commonly used 520 flavivirus vaccines. Healthy study participants were enrolled into cohorts receiving vaccines 521 against TBEV and YFV in different or the same upper arm, JEV and YFV in different or the 522 same upper arm, and in control cohorts receiving vaccines against TBEV, JEV, or YFV. Co-523 administration of the TBEV or JEV vaccine with the YFV vaccine was well tolerated with 524 respect to reported AEs. Clinical virology, chemistry, and immunological assessments supported 525 these conclusions with no markedly unexpected responses observed. Serological responses 526 including virus-specific IgG levels and virus-specific nAb titers towards individual viruses were 527 not adversely affected by concomitant vaccination. Additional immunological studies added 528 deeper immunological insights into vaccine responses in concomitantly vaccinated study 529 participants and controls.

530 Of the AEs reported following vaccination, the majority were mild, dominated by 531 common cold symptoms followed by classical reactogenicity-related responses. The majority of 532 the reported AEs were deemed unrelated to vaccination. AEs related to vaccination (deemed 533 possible or probable) were in line with previous safety data of single vaccination studies and the 534 manufacturer's reported known side effects [15–17,44–46]. YFV RNA levels were generally 535 similar between the concomitant and YFV only vaccine cohort, supported by normal clinical 536 chemistry inflammation-, liver- and kidney-related parameters. Additionally, no marked 537 differences were observed in absolute CD45⁺, CD4⁺, or CD8⁺ cell counts as well as TNF or IL-538 18 levels as well as other cytokine levels (data not shown), between concomitant and single vaccination cohorts. 539

540 Earlier studies have shown the possible enhancement of cross-reactive flavivirus-specific cellular and humoral immunity after flavivirus vaccinations [47–50]. These observations led us 541 542 to address if concomitant vaccination of flavivirus vaccines had any deviating effect on the 543 generation of virus-specific IgG and/or nAbs as well as on other immunological outcomes. All 544 TBEV vaccinated study participants were well above the defined positive threshold and were 545 found to have overall similar median IgG levels and nAb titers. In a similar manner, we assessed 546 JEV-specific IgG and nAbs in the JEV vaccine cohorts. All but four study participants developed 547 JEV-specific IgG levels above the positive threshold at the end of study with no differences 548 between the concomitant vaccine cohorts and the single JEV vaccine cohort. Not all study 549 participants receiving the JEV vaccine developed nAbs by the end of the study. Finally, all study 550 participants receiving the YFV vaccine developed nAbs by the end of the study and no 551 differences were found between the concomitant and YFV vaccine only cohorts. The findings suggest that concomitant vaccination had no general negative effect on the development of 552 553 protective virus-specific serological responses.

554 In addition to assessing the effect of concomitant vaccination on serological outcomes, we also assessed effects on lymphocyte activation and, in more detail, germinal center and 555 556 plasmablast responses. As expected, NK cell, T cell, and B cell activation was observed in the 557 cohorts receiving the live attenuated YFV vaccine (cohorts A1, A2, B1, B2 and E) in line with 558 previous research [42,43,51]. Cohorts C and D showed little to no increase in activation of these 559 cell subsets throughout the study, not unexpected from the inactivated TBEV and JEV vaccines, 560 respectively. Despite the lack of early cellular activation amongst cohorts C and D, this had no 561 effect on the outcome of development of TBEV and JEV nAbs as assessed at the end of the 562 study. Similar patterns were observed in plasmablast expansion, a B cell subset responsible for

563 secreting large amounts of antibodies following infection or vaccination [52]. Plasmablasts expanded robustly in cohorts receiving the YFV vaccine (cohorts A1, A2, B1, B2 and E), a 564 565 finding consistent with previous studies of YFV vaccinated individuals [42,43,51,53–58]. 566 Plasmablast expansion was not observed in the TBEV or JEV only cohorts (cohorts C and D) 567 upon primary vaccination. However, subsequent doses of TBEV or JEV vaccines led to detection 568 of some plasmablast expansion. As plasmablasts can derive from previously generated memory 569 B cells [59,60], more expansions may be expected after several doses of TBEV or JEV vaccine. 570 In summary, few differences in immunological responses were observed between concomitant 571 flavivirus vaccination and single vaccination, much of the responses observed likely due to the YFV vaccine. 572

573 Co-administration of vaccines into the same or different upper arms allowed for 574 comparative studies between these different strategies of administering two different vaccines. One advantage with administrating vaccines in the same upper arm (or at the same site in 575 576 general) is that the other upper arm is not affected in terms of local reactogenicity responses. 577 That may save the dominant arm from possible functional impairment over the first days 578 following vaccination. As mentioned, no statistically significant differences between the study 579 and control cohorts' TNF or IL-18 serum comparing cohorts A1 with A2 or B1 with B2 were observed. Similarly, no statistical differences were found in terms of the development of virus-580 581 specific nAbs between the A1 and A2 or B1 and B2 cohorts as well as other B cell-related 582 responses including activation and plasmablasts expansion. The only observed statistically 583 significant difference noted between the same arm (A2 and B2) and different arm (A1 and B1) 584 concomitant vaccine cohorts was the frequency of activated CD4⁺ T cells being higher in cohort 585 B2 versus cohort B1. This said, TNF and IL-18, general lymphocyte activation, nAb titers, as

well as percentages of plasmablasts, were if anything slightly higher in the study groups where
concomitant vaccination had occurred in the same upper arm (A2 and B2) versus different upper
arms (A1 and B1). We cannot exclude the possibilities that adjuvant-like effects imposed by,
e.g., the live attenuated YFV vaccine or priming of immune cells in the same lymph node might
contribute to the effects observed.

591 The relative strength of the present study is that data were collected from a *bona fide* 592 prospective clinical trial with the scientific and regulatory rigor inherent to this design, 593 independent study monitoring of data, both of which contributed to data quality, and additionally 594 low drop-out rates and minimal risk of selection bias. An additional advantage was the ability to 595 include and compare two different inactivated whole virus vaccines, the TBEV and JEV 596 vaccines, respectively. The study contributes carefully evaluated clinical safety data in addition 597 to standard clinical virology, clinical chemistry, and clinical immunology data. The number and 598 frequency of study participant visits added to the strength of the study. With respect to 599 limitations of this study, even later sampling time-points would have allowed assessment of 600 sustainability of the developed nAbs and larger study groups could have given even more robust 601 data. Another relative limitation of the study is the fact that it did not include screening for 602 TBEV, JEV or YFV seropositivity prior to enrollment into the study. However, only two study 603 participants with positive nAbs against TBEV and no one to JEV or YFV were identified. 604 Concomitant vaccine administration strategies have been used in many child vaccination 605 programs [61,62] as well with travelers on their way to endemic regions [25,63]. Administration 606 of multiple vaccines at the same time is convenient as it reduces the number of clinical visits, 607 thus saving time and resources, and provides protection against multiple pathogens in a shorter

time-span when an individual may be vulnerable to infection. In addition, most reports deem

609 concomitant vaccinations safe and effective [25,29,64,65]. In this respect, the guidelines of the 610 US Food and Drug Administration (FDA) regarding the YFV vaccine YF-Vax (Sanofi Pasteur) 611 state that it can be administered with the that measles vaccine, diphtheria and tetanus toxoid and 612 whole cell pertussis vaccine (DTP), Hepatitis A and B vaccines, meningococcal vaccine, and 613 typhoid vaccine (www.fda.gov). Most regulatory authorities including the Swedish Medical 614 Products Agency recommend concomitant delivery of many vaccines, including the YFV 615 vaccine, at separate injection sites (www.lakemedelsverket.se/en). With respect to flavivirus 616 vaccines, the FDA specifically notes that the potential interference between the YFV vaccine and 617 JEV vaccines have not been established. In context of the COVID-19 pandemic, new vaccine 618 technologies have been successfully implemented and are now being tested when administered 619 concomitantly with seasonal influenza vaccines. The safety and immunogenicity data generated 620 from this clinical trial can provide insights into concomitant vaccination strategies using different 621 types of vaccine formulations that could aid in guiding new vaccination strategies of emerging 622 and re-emerging viral infections.

In conclusion, this clinical trial showed that concomitant TBEV or JEV vaccination with the live attenuated YFV vaccine can be administered with little risk of severe adverse events and, additionally, no impairment on the development of nAbs to the respective viruses. Finally, the vaccines can readily be administered in the same upper arm.

627 Acknowledgments

628	We thank all study participants for participating in the clinical trial, the Karolinska Trial Alliance
629	staff and research nurses for organizing the recruitment and scheduling of study participants,
630	vaccination, and clinical sampling. Additionally, we thank J. Verner-Carlsson and staff scientists
631	at the Swedish Public Health Agency for support with neutralization assays and BSL-3
632	instruction. Further thanks to W. Christ for support in the BSL-3 facility, P. Jahnmatz for
633	discussions around the FluoroSpot reader assessment, and D. Wullimann for discussions and
634	advice on the project.
635	
636	Author Contributions
637	Conceptualization: KB and H-GL; data curation: JTS, ML, KB; formal analysis: JTS, ML, KB;
638	funding acquisition: KB, H-GL; investigation: JTS, ML, RV, JE, KB; development of
639	methodology: JTS, ML, KB, KL; management and coordination responsibility: JTS, ML, KB, H-
640	GL; provision of study materials and samples: NA-T, LL, KB, H-GL; oversight and leadership:
641	JK, KL, KB, H-GL; verification: JTS, ML, NA-T, JK, KB; data visualization: JTS, ML, KB, H-
642	GL; writing initial draft: JTS, ML, KB, H-GL; manuscript review and revision: JTS, ML, RV,
643	JE, NA-T, LL, SG-R, JK, KL, KB, H-GL.
644	
645	
646	
647	
648	

649 **References**

1. Daep CA, Muñoz-Jordán JL, Eugenin EA. Flaviviruses, an expanding threat in public health:
focus on dengue, West Nile, and Japanese encephalitis virus. J Neurovirol. 2014;20: 539–560.
doi:10.1007/s13365-014-0285-z

- 653 2. Gershman MD, Staples JE. Netter's Infectious Diseases. Sect Vii Infect Assoc Int Travel
 654 Outdoor Activities. 2012; 383–389. doi:10.1016/b978-1-4377-0126-5.00064-1
- 3. Dumpis U, Crook D, Oksi J. Tick-Borne Encephalitis. Clin Infect Dis. 1999;28: 882–890.
 doi:10.1086/515195
- 4. Haglund M, Gunther G. Tick-borne encephalitis—pathogenesis, clinical course and long-term
 follow-up. Vaccine. 2003;21: S11--S18. doi:10.1016/s0264-410x(02)00811-3
- 5. Yellow fever. 7 May 2019 [cited 2 Feb 2022]. Available: https://www.who.int/news room/fact-sheets/detail/yellow-fever
- 6. Bogovič P, Lotrič-Furlan S, Avšič-Županc T, Korva M, Kastrin A, Lusa L, et al. Comparison
- of Clinical, Laboratory and Immune Characteristics of the Monophasic and Biphasic Course of
- Tick-Borne Encephalitis. Microorg. 2021;9: 796. doi:10.3390/microorganisms9040796
- 7. Borah J, Dutta P, Khan SA, Mahanta J. A comparison of clinical features of Japanese
 encephalitis virus infection in the adult and pediatric age group with Acute Encephalitis
 Syndrome. J Clin Virol. 2011;52: 45–49. doi:10.1016/j.jcv.2011.06.001
- 667 8. Tick-borne encephalitis. 2 Oct 2017 [cited 2 Feb 2022]. Available:
- 668 https://www.who.int/health-topics/tick-borne-encephalitis#tab=tab_1
- 669 9. Japanese encephalitis. 9 May 2019 [cited 2 Feb 2022]. Available:
- 670 https://www.who.int/en/news-room/fact-sheets/detail/japanese-encephalitis
- 10. Riccardi N, Antonello RM, Luzzati R, Zajkowska J, Bella SD, Giacobbe DR. Tick-borne
- 672 encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment. Eur
- 673 J Intern Med. 2019;62: 1–6. doi:10.1016/j.ejim.2019.01.004
- 11. Son H, Sunwoo J-S, Lee SK, Chu K, Lee S-T. Clinical Outcomes of Japanese Encephalitis
- after Combination Treatment of Immunoglobulin, Ribavirin, and Interferon-α2b. J Clin Neurol.
 2021;17: 428–434. doi:10.3988/jcn.2021.17.3.428
- 12. Douam F, Ploss A. Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old
 Foe. Trends Microbiol. 2018;26: 913–928. doi:10.1016/j.tim.2018.05.012

- 13. Tokunaga M, Miyamoto Y, Suzuki T, Otani M, Inuki S, Esaki T, et al. Novel anti-flavivirus
- drugs targeting the nucleolar distribution of core protein. Virology. 2020;541: 41–51.
- 681 doi:10.1016/j.virol.2019.11.015
- 682 14. Felicetti T, Manfroni G, Cecchetti V, Cannalire R. Broad-Spectrum Flavivirus Inhibitors: a
- 683 Medicinal Chemistry Point of View. Chemmedchem. 2020;15: 2391–2419.
- 684 doi:10.1002/cmdc.202000464
- 685 15. FSME-IMMUN Vuxen FASS Vårdpersonal. [cited 16 Nov 2021]. Available:
- https://www.fass.se/LIF/product?userType=0&nplId=20040206000026&docType=7&scrollPosit
 ion=255
- 16. IXIARO® FASS Vårdpersonal. [cited 16 Nov 2021]. Available:
 https://www.fass.se/LIF/product?userType=0&nplId=20080207000014
- 690 17. Stamaril® FASS Vårdpersonal. [cited 16 Nov 2021]. Available:
- 691 https://www.fass.se/LIF/product?userType=0&nplId=19940408000036
- 692 18. Gotuzzo E, Yactayo S, Cordova E. Review article: Efficacy and duration of immunity after
- 693 yellow fever vaccination: Systematic review on the need for a booster every 10 years. Am J
- 694 Tropical Medicine Hyg. 2013;89: 434--444. doi:10.4269/ajtmh.13-0264
- 19. Plotkin SA. Correlates of Protection Induced by Vaccination v. Clin Vaccine Immunol.
 2010;17: 1055–1065. doi:10.1128/cvi.00131-10
- 697 20. Plotkin SA, Orenstein WA, Offit P, Edwards KM. Plotkin's Vaccines. 7th Editio.
 698 Philadelphia, PA: Elsevier; 2017.
- 699 21. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371: 1861--1871.
 700 doi:10.1016/s0140-6736(08)60800-4
- 22. Björk A, Morelli V. Immunization Strategies for Healthcare Practices and Providers | CDC.
- In: Immunization Strategies for Healthcare Practices and Providers [Internet]. 2021 [cited 20 Feb
 2022]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/strat.html
- Ambrosch F, Fritzell B, Gregor J, Jonas S, Kollaritsch H, Teulieres L, et al. Combined
 vaccination against yellow fever and typhoid fever: a comparative trial. Vaccine. 1994;12: 625–
 628. doi:10.1016/0264-410x(94)90267-4
- 24. Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, et al. Concomitant or
 sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and
 yellow fever 17D vaccine. Hum Vaccines. 2010;6: 906–914. doi:10.4161/hv.6.11.12854
- 25. Jelinek T, Cramer JP, Dieckmann S, Hatz C, Paulke-Korinek M, Alberer M, et al. Evaluation
 of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine

- administered concomitantly with a Japanese encephalitis vaccine. Travel Med Infect Di.
- 713 2015;13: 241–250. doi:10.1016/j.tmaid.2015.05.008
- 714 26. López P, Lanata CF, Zambrano B, Cortés M, Andrade T, Amemiya I, et al. Immunogenicity
- and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a
- 716 Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in
- 717 Colombia and Peru. Pediatric Infect Dis J. 2016;35: 1140–1147.
- 718 doi:10.1097/inf.000000000001250
- 719 27. Silva JRN, Camacho LAB, Siqueira MM, Freire M de S, Castro YP, Maia M de LS, et al.
- 720 Mutual interference on the immune response to yellow fever vaccine and a combined vaccine
- against measles, mumps and rubella. Vaccine. 2011;29: 6327–6334.
- 722 doi:10.1016/j.vaccine.2011.05.019
- 723 28. Kreil TR, Burger I, Attakpah E, Olas K, Eibl MM. Passive immunization reduces immunity
- that results from simultaneous active immunization against tick-borne encephalitis virus in a
- 725 mouse model. Vaccine. 1998;16: 955–959. doi:10.1016/s0264-410x(97)00304-6
- 726 29. Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, Kollaritsch H, et al. Safety
- and immunogenicity of concomitant vaccination with the cell-culture based Japanese
- Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX®1440 in healthy subjects: A
- single-blind, randomized, controlled Phase 3 study. Vaccine. 2009;27: 4483–4489.
- 730 doi:10.1016/j.vaccine.2009.05.034
- 30. Konishi E, Terazawa A, Imoto J. Simultaneous immunization with DNA and protein
- vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to
- induce neutralizing antibody in mice. Vaccine. 2003;21: 1826–1832. doi:10.1016/s0264-
- 734 410x(03)00028-8
- 31. Fletcher MA, Fabre P, Debois H, Saliou P. Vaccines administered simultaneously: directions
- for new combination vaccines based on an historical review of the literature. Int J Infect Dis.
- 737 2004;8: 328–338. doi:10.1016/j.ijid.2004.03.006
- 738 32. Pilewski KA, Kramer KJ, Georgiev IS. Simultaneous Immunization with Multiple Diverse
- 739 Immunogens Alters Development of Antigen-Specific Antibody-Mediated Immunity. Nato Adv
 740 Sci Inst Se. 2021;9: 964. doi:10.3390/vaccines9090964
- 741 33. Coursaget P, Fritzell B, Blondeau C, Saliou P, Diop-Mar I. Simultaneous injection of
- 742 plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines.
- 743 Vaccine. 1995;13: 109–111. doi:10.1016/0264-410x(95)80020-e
- 744 34. Tauraso NM, Myers MG, Nau EV, O'Brien TC, Spindel SS, Trimmer RW. Effect of interval
 745 between inoculation of live smallpox and yellow-fever vaccines on antigenicity in man. J Infect
- 746 Dis. 1972;126: 362–71. doi:10.1093/infdis/126.4.362

747 35. Felsenfeld O, Wolf RobertH, Gyr K, Grant LouisS, Dutta NirmalK, Zarifi AZ, et al.

748 SIMULTANEOUS VACCINATION AGAINST CHOLERA AND YELLOW FEVER. Lancet.
749 1973;301: 457–458. doi:10.1016/s0140-6736(73)91882-5

36. Kaaijk P, Luytjes W. Are we prepared for emerging flaviviruses in Europe? Challenges for
vaccination. Hum Vacc Immunother. 2017;14: 337–344. doi:10.1080/21645515.2017.1389363

- 752 37. Lukan M, Bullova E, Petko B. Climate Warming and Tick-borne Encephalitis, Slovakia -
- 753 Volume 16, Number 3—March 2010 Emerging Infectious Diseases journal CDC. Emerg
- 754 Infect Dis. 2010;16: 524–526. doi:10.3201/eid1603.081364
- 38. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. Nat Microbiol.
 2020;5: 796–812. doi:10.1038/s41564-020-0714-0
- 757 39. ICH GCP ICH harmonised guideline integrated addendum to ICH E6(R1): Guideline for
- 758 Good Clinical Practice ICH E6(R2) ICH Consensus Guideline ICH GCP. [cited 31 Jan 2022].
- 759 Available: https://ichgcp.net/sv
- 40. Miller JD, Most RG van der, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human
- 761 Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines.
- 762 Immunity. 2008;28: 710--722. doi:10.1016/j.immuni.2008.02.020

41. Vene S, Haglund M, Vapalahti O, Lundkvist A. A rapid fluorescent focus inhibition test for
detection of neutralizing antibodies to tick-borne encephalitis virus. J Virol Methods. 1998;73:
71--75. doi:10.1016/s0166-0934(98)00041-x

- 766 42. Marquardt N, Ivarsson MA, Blom K, Gonzalez VD, Braun M, Falconer K, et al. The Human
- 767 NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed by NK Cell Differentiation
- 768 Independently of NK Cell Education. J Immunol. 2015;195: 3262--3272.
- 769 doi:10.4049/jimmunol.1401811
- 43. Sandberg JT, Ols S, Löfling M, Varnaitė R, Lindgren G, Nilsson O, et al. Activation and
- 771 Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and
- 772 Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination. J Immunol.
- 773 2021;207: ji2001381. doi:10.4049/jimmunol.2001381
- 44. Loew-Baselli A, Konior R, Pavlova BG, Fritsch S, Poellabauer E, Maritsch F, et al. Safety
- and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN®:
- Results of two large phase 3 clinical studies. Vaccine. 2006;24: 5256–5263.
- 777 doi:10.1016/j.vaccine.2006.03.061
- 45. Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Müller Z. Safety profile of the
- 779 Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO®. Vaccine. 2011;29:
- 780 8669–8676. doi:10.1016/j.vaccine.2011.08.117

- 46. Cottin P, Niedrig M, Domingo C. Safety profile of the yellow fever vaccine Stamaril®: a 17year review. Expert Rev Vaccines. 2014;12: 1351–1368. doi:10.1586/14760584.2013.836320
- 47. Blom K, Sandberg JT, Loré K, Ljunggren H-G. Prospects for induction of CD8 T cellmediated immunity to Zika virus infection by yellow fever virus vaccination. J Intern Med.
 2017;282: 206–208. doi:10.1111/joim.12638
- 48. Lobigs M, Diamond MS. Feasibility of cross-protective vaccination against flaviviruses of
 the Japanese encephalitis serocomplex. Expert Rev Vaccines. 2014;11: 177–187.
- 788 doi:10.1586/erv.11.180
- 49. Saron WAA, Rathore APS, Ting L, Ooi EE, Low J, Abraham SN, et al. Flavivirus
- serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T
 cells. Sci Adv. 2018;4: eaar4297. doi:10.1126/sciadv.aar4297
- 50. Yamshchikov G, Borisevich V, Kwok CW, Nistler R, Kohlmeier J, Seregin A, et al. The
- suitability of yellow fever and Japanese encephalitis vaccines for immunization against West
- 794 Nile virus. Vaccine. 2005;23: 4785–4792. doi:10.1016/j.vaccine.2005.04.036
- 51. Blom K, Braun M, Ivarsson MA, Gonzalez VD, Falconer K, Moll M, et al. Temporal
- dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an
- 797 effector- to a memory-type response. J Immunol. 2013;190: 2150--8.
 798 doi:10.4049/jimmunol.1202234
- 52. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting
 plasma cells. Nat Rev Immunol. 2015;15: 160–171. doi:10.1038/nri3795
- 801 53. Wieten RW, Jonker EFF, Leeuwen EMMV, Remmerswaal EBM, Berge IJMT, Visser AWD,
- et al. A single 17D yellow fever vaccination provides lifelong immunity; characterization of
 yellow-fever-specific neutralizing antibody and T-cell responses after vaccination. Shoukry NH,
- editor. Plos One. 2016;11: e0149871. doi:10.1371/journal.pone.0149871
- 54. Azamor T, Silva AMV da, Melgaço JG, Santos AP dos, Xavier-Carvalho C, Alvarado-Arnez
 LE, et al. Activation of an Effective Immune Response after Yellow Fever Vaccination Is
- Associated with the Genetic Background and Early Response of IFN-γ and CLEC5A. Viruses.
 2021;13: 96. doi:10.3390/v13010096
- 809 55. Martins MÂ, Silva ML, Marciano APV, Peruhype-Magalhães V, Eloi-Santos SM, Ribeiro
- 810JGL, et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD
- 811 yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following
- 812 immunization? Clin Exp Immunol. 2007;148: 90–100. doi:10.1111/j.1365-2249.2006.03317.x
- 813 56. Davydov AN, Obraztsova AS, Lebedin MY, Turchaninova MA, Staroverov DB, Merzlyak
- EM, et al. Comparative Analysis of B-Cell Receptor Repertoires Induced by Live Yellow Fever
- 815 Vaccine in Young and Middle-Age Donors. Front Immunol. 2018;9: 2309.
- 816 doi:10.3389/fimmu.2018.02309

- 57. Costa-Rocha IA da, Campi-Azevedo AC, Peruhype-Magalhães V, Coelho-dos-Reis JG,
- 818 Fradico JRB, Souza-Lopes T, et al. Duration of Humoral and Cellular Immunity 8 Years After
- Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine. Front Immunol. 2019;10:
- 820 1211. doi:10.3389/fimmu.2019.01211
- 58. Huber JE, Ahlfeld J, Scheck MK, Zaucha M, Witter K, Lehmann L, et al. Dynamic changes
- in circulating T follicular helper cell composition predict neutralising antibody responses after
- yellow fever vaccination. Clin Transl Immunol. 2020;9: 1--16. doi:10.1002/cti2.1129
- 59. Priyamvada L, Cho A, Onlamoon N, Zheng N-Y, Huang M, Kovalenkov Y, et al. B Cell
 Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive,
 Memory-Derived Plasmablasts. J Virol. 2016;90: 5574–5585. doi:10.1128/jvi.03203-15
- 60. Sundling C, Lau AWY, Bourne K, Young C, Laurianto C, Hermes JR, et al. Positive
- selection of IgG+ over IgM+ B cells in the germinal center reaction. Immunity. 2021;54: 1--14.
 doi:10.1016/j.immuni.2021.03.013
- 830 61. Zhao Z, Smith PJ, Hill HA. Evaluation of potentially achievable vaccination coverage with
- simultaneous administration of vaccines among children in the United States. Vaccine. 2016;34:
- 832 3030–3036. doi:10.1016/j.vaccine.2016.04.097
- 62. HESLEY TM, REISINGER KS, SULLIVAN BJ, JENSEN EH, STASIOROWSKI S,
- 834 MEECHAN CD, et al. Concomitant administration of a bivalent Haemophilus influenzae type b-
- hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety,
- tolerability and immunogenicity. Pediatric Infect Dis J. 2004;23: 240–245.
- 837 doi:10.1097/01.inf.0000114902.84651.02
- 838 63. Hoecke C, Lebacq E, Beran J, Prymula R, Collard F. Concomitant Vaccination against
- Hepatitis A and Typhoid Fever. J Travel Med. 1998;5: 116–120. doi:10.1111/j.17088305.1998.tb00483.x
- 64. Wang SV, Abdurrob A, Spoendlin J, Lewis E, Newcomer SR, Fireman B, et al. Methods for
- 842 addressing "innocent bystanders" when evaluating safety of concomitant vaccines.
- 843 Pharmacoepidem Dr S. 2018;27: 405–412. doi:10.1002/pds.4399
- 65. Falsey AR, Walsh EE, Scott DA, Gurtman A, Zareba A, Jansen KU, et al. Phase 1/2
- 845 Randomized Study of the Immunogenicity, Safety and Tolerability of an RSV Prefusion F
- 846 Vaccine in Adults With Concomitant Inactivated Influenza Vaccine. J Infect Dis. 2021; jiab611-.
- 847 doi:10.1093/infdis/jiab611
- 848
- 849

850 Supporting information

851 S1 Fig. Soluble cytokine concentrations in serum following vaccination. (A) Heat map of

- 852 fold changes of all detectable soluble factors in serum following vaccination. (B) Box and
- 853 whisker plots comparing serum TNF and IL-18 concentrations following the first vaccine dose.
- The legend denotes color-coding of the seven cohorts. Statistical analyses were performed using
- 855 nonparametric Friedman and Kruskal-Wallis test with Dunn's multiple comparison tests.

856 S2 Fig. Sex-based comparisons of final virus nAb titers. (A) Comparisons of male (M) vs female (F)

TBEV nAb titers at the final time point in cohort A1 and A2 (left panel), cohort C (middle panel) and

858 combined A and C cohorts (right panel). (B) Comparisons of male (M) vs female (F) JEV nAb titers at

the final time point in cohort B1 and B2 (left panel), cohort D (middle panel) and combined B and D

cohorts (right panel). (C) Comparisons of male (M) vs female (F) YFV nAb titers at the final time point

in cohort E (left panel) and combined A, B, and E cohorts (right panel). The legend denotes color-coding

- 862 of the seven cohorts. Statistical analyses were performed using nonparametric Friedman and Kruskal-
- 863 Wallis test with Dunn's multiple comparison tests. *p < 0.05.

864 S3 Fig. Immunoglobulin expression of circulating plasmablasts. (A) Median IgG expression

of plasmablasts over time following vaccination and comparison of peak expression between

cohorts at days (B) 14, (C) 37 and (D) 187. (E) Median IgA expression of plasmablasts over time

- following vaccination and (F) comparison of lowest expression between cohorts at day14. (G)
- 868 Median IgG-A- expression of plasmablasts over time following vaccination and (H) comparison
- of peak expression between cohorts at day14. The legend denotes color-coding of the seven
- 870 cohorts. All plots are depicted with median values with IQR. Statistical analyses were performed

- using nonparametric Kruskal-Wallis test with Dunn's multiple comparison tests. *p < 0.05, **p
- **872** < 0.01, ***p < 0.001.
- 873 S1 Table. List of adverse events following vaccination
- 874 S2 Table. Summary of registered adverse events


875 FIGURE LEGENDS


876 Fig. 1 | Clinical trial layout for study participants and vaccination strategy with sampling 877 timeline. (A) The flowchart depicts the screening and enrollment of healthy volunteers in the 878 study. Enrolled study participants were divided into seven vaccine cohorts. Study participant 879 dropouts and total missed visits are depicted. (B) Schematic of vaccination strategy and sampling 880 schedule for enrolled study participants. Peripheral blood and serum samples were taken at the 881 time-points indicated by blood drop symbol. See Material and Methods for vaccination details. 882 883 Fig. 2 | Clinical laboratory assessment following concomitant flavivirus vaccination. (A) 884 Total number of YFV RNA copies/mL serum in cohorts receiving YFV vaccine. (B) Comparison 885 of day 7 YFV RNA copies/mL between cohorts (plot depicts median with IQR). (C) Median 886 clinical chemistry data-points during first four time-points of the study. Grey backgrounds 887 denote the normal range in healthy adults. (D) Total numbers of CD45⁺, CD4⁺, and CD8⁺ cells 888 over time following vaccination (left panels) and comparison of day 14 median absolute cell 889 numbers in the respective vaccine cohorts (right panels, plots depict median with IQR). (E) Heat-890 map of fold change of serum TNF and IL-18 levels following the first vaccine dose. The legend 891 denotes color-coding of the seven cohorts. Statistical analyses in (A), (C), and (E) were 892 performed using nonparametric Friedman test with Dunn's multiple comparison tests, in (B) and 893 (D day 14 plots), using nonparametric Kruskal-Wallis test with Dunn's multiple comparison 894 tests, and in (**D** timeline) using nonparametric Wilcoxon matched-pairs signed-rank tests. *p < 0.05, **p < 0.01, ***p < 0.001. 895


896


897	Fig. 3 Seroconversion and development of neutralizing antibody following concomitant
898	flavivirus vaccination. (A) TBEV specific IgG levels before and after concomitant vaccination
899	with TBEV and YFV or only TBEV. The dotted line denotes manufacturer's positive threshold
900	and samples ≥1000 Vienna units were plotted at 1000 Vienna units. (B) Comparisons of final
901	TBEV-specific IgG levels between cohorts A1, A2 and C. (C) JEV specific IgG levels before
902	and after concomitant vaccination with JEV and YFV or only JEV. The dotted line denotes
903	manufacturer's positive threshold and samples \geq 200 RU/mL were plotted at 200 RU/mL. (D)
904	Comparisons of final JEV-specific IgG levels between cohorts B1, B2 and D. (E) TBEV
905	neutralizing antibody titers before and at days 30 and 210 after concomitant vaccination with
906	TBEV and YFV or only TBEV. Study participants with nAbs detected at day 0 (A1, n =1; A2, n
907	= 1) excluded from figures. The dotted line denotes positive threshold (\geq 5). (F) Comparisons of
908	final nAb titers against TBEV between cohorts (percent seropositive individuals as denoted
909	above). (G) JEV neutralizing antibody titers before and at days 30 and 60 after concomitant
910	vaccination against JEV and YFV or only JEV. Dotted line denotes positive threshold (\geq 5). (H)
911	Comparisons of final nAbs titers against JEV between cohorts (percent seropositive individuals
912	as denoted above). (I) YFV neutralizing antibody titers before and at days 30 and 60 after
913	concomitant vaccination with TBEV or JEV and YFV, or only YFV. The dotted line denotes
914	positive threshold (\geq 5). (J) Comparisons of final nAbs titers against YFV between respective
915	cohorts. The legend denotes color coding of the seven cohorts. All plots are depicted with
916	median values. Statistical analyses in (A), (C), (E), (G), and (I) were performed using
917	nonparametric Friedman test with Dunn's multiple comparison tests and in (B), (D), (F), (H),
918	and (J) using nonparametric Kruskal-Wallis test with Dunn's multiple comparison tests. $*p <$
919	0.05, **p < 0.01, ***p < 0.001.


921	Fig. 4 B cell, T cell and NK cell activation following concomitant flavivirus vaccination.
922	(A) Representative gating strategy identifying B cells, CD4 ⁺ and CD8 ⁺ T cells as well as
923	CD56 ^{dim} NK cells. Representative FACS plot of CD38 ⁺ Ki67 ⁺ (B) B cells, (C) CD4 ⁺ T cells, (D)
924	CD8 ⁺ T cells, and (E) CD56 ^{dim} NK cells (left panels) with corresponding plot of the respective
925	cohorts' frequency of activation medians before and following vaccination program (middle
926	panels). Plots comparing peak activation at day 14 between the vaccination cohorts (right panels
927	depicting median values with IQR). The legend denotes color-coding of the seven cohorts.
928	Statistical analyses were performed using nonparametric Kruskal-Wallis test with Dunn's
929	multiple comparison tests. $*p < 0.05$ and $***p < 0.001$.
930	
930 931	Fig. 5 Germinal center activity and plasmablast expansion following concomitant
	Fig. 5 Germinal center activity and plasmablast expansion following concomitant flavivirus vaccination. (A) Median CXCL13 serum fold changes over time following
931	
931 932	flavivirus vaccination. (A) Median CXCL13 serum fold changes over time following
931 932 933	flavivirus vaccination. (A) Median CXCL13 serum fold changes over time following vaccination program (left panel), and comparison of peak levels between cohorts at days 7 and
931 932 933 934	 flavivirus vaccination. (A) Median CXCL13 serum fold changes over time following vaccination program (left panel), and comparison of peak levels between cohorts at days 7 and 14 (right panel). (B) Representative gating strategy for identifying plasmablasts. (C) Median
931 932 933 934 935	 flavivirus vaccination. (A) Median CXCL13 serum fold changes over time following vaccination program (left panel), and comparison of peak levels between cohorts at days 7 and 14 (right panel). (B) Representative gating strategy for identifying plasmablasts. (C) Median plasmablast expansion over time following vaccination and (D) comparison of peak expansion




















S Table 1 Adverse events after vaccination

Cohort A1

Outloor among along 2 AE	Mid		Moderate		Severe		Total		Total
System organ class & AE	R	NR	R	NR	R	NR	R	NR	B+NR
General disorders and administrative site conditions									
Flu like symtoms	1						1		1
Chils									
Injection site abscess	1						1		1
Pain/redness at site	7						7		7
Fatigue	2						2		2
Nervous system disorders									
Headache		3		1				4	4
Lack of sleep									
Musculoskeletal and connecity tissue dissorders									
Joint pain		1						1	1
Back pain		1						1	1
Muscle (body) pain	1	1					1	1	2
Gastro-intestinal disorders									
Toothache		1						1	1
Nausea/vomiting		1		-				1	1
Respiratory, thoracic and mediastinal disorders									
Cough									
Som throat		3						3	3
Asthma									
Metabolism and nutrition disorders					-				
Diabetes type 2				1				1	1
Infections and Infestations									
Upper respiratory intection	4	8					4	8	12
Injury, poisoning and procedural complications									
Bruising	1						1		1
Fal				1		1		2	2
Ear and labyrinth disorders									
Middle ear inflammation				1				1	1
Reproductive system and breast disorders									
Scrotal pain		1						1	1
Total	17	20		4		1	17	25	42

Cohort B1

0-1	N.	Aid	Mod	ierate	Sev	010	To	tal	Total	1
System organ class & AE	R	NR	R	NR	R	NR	R	NR	B+NR	
General dinedRxiv proprint doi:=Https://clonord/404	1101/20	22.07	05.222	277040	; this v	ersion	poste	d July	11, 20	22. TH
Fever (which was not certified by peer rev										
	lt is mac									
Pain/redness at sile	1						1		1	1 1
Nervous system disorders										1 I
Headache		1		1				2	2	1 I
Musculoskeletal and connectly tissue dissorders										1 1
Joint pain	1	1					1	1	2	I I
Muscle (body) pain	1						1		1	1 1
Gastro-Intestinal disorders										1 1
Gastric ulcer		1						1	1	
Dianhea		1						1	1	1 1
Reproductive system and breast disorders										1 [
Dysmonombea		2						2	2	1 1
Respiratory, thoracic and mediastinal disorders										1 1
Cough				1				1	1	1 1
Sore throat		2						2	2	1 0
Allergic minitis		1						1	1	1 1
Infections and Infestations										
Upper respiratory infection		3		1				4	4	
Psychiatric disorders										
Depression			1				1		1	I D
Others (no SOC)										I F
Heel sours		1						1	1	
Total	8	16	1	3			7	19	28	· 1

Cohort C

Outras amon alters & AF	N	hid	Mod	erate	Se	vere	To	Mal	Total
System organ class & AE	R	NR	R	NR	R	NR	R	NR	R+NR
General disorders and administrative sile conditions									
Fever		1	1				1	1	2
Pain/redness at sile	- 4						4		4
Fatigue	1						1		1
Nervous system disorders									
Headache	1	2					1	2	3
Dizziness				1				1	1
Musculoskeletal and connecity tissue dissorders									
Muscle (body) pain	1						1		1
Gastro-Intestinal disorders									
Other (Stomach flu				1				1	1
Nausea/vomiting	1		1				2		2
Diarrhea		1						1	1
Metabolism and nutrition disorders									
Other (Iron deliciency		1						1	1
Infections and infestations									
Upper respiratory infection (forkylning)	3	7	1	1			4	8	12
Respiratory, thoracic and mediastinal disorders									
Asthma				1				1	1
Injury, poisoning and procedural complications Other (Cut, bite			-	1				1	1
Reproductive system and breast disorders									
Dysmenomea	2	2					2	2	4
Psychiatric disorders									
Depression						1		1	1
Anxiety				1				1	1
Total	13	14	3	8		1	16	21	37


System organ class & AE		Nd	Mod	erate	Se	vere	To	tal	Total
	R	NR	R	NR	R	NR	R	NR	R+NF
General disorders and administrative site conditions						_			
Fever	1	3					1	3	4
Flu like symfoms Injection site abscess	1	1	1	1		-	1	2	3
Pain/redness at sile	6	1					6	1	7
Falique	1		-	1		-	1	1	2
Nervous system disorders		-							
Headache	2	2	2				4	2	6
Musculoskeletal and connectly tissue dissorders					-		4		
Muscle (body) pain		1						1	2
Gastro-intestinal disorders									
Other (Stomach flu				1				1	1
Respiratory, thoracic and mediastinal disorders									
Cough									
Sore throat									
Asthma		1						1	
Other (Iron deliciency		1						1	1
Infections and infestations		1.1							
Upper respiratory infection (forkylning)		11		1				12	12
Urinary tract infection		1		1				2	2
Vaginal infection		2		1				3	3
Other (HSV		1						1	1
Injury, polsoning and procedural complications									1
Bruising			1				1		1
Other (Qut,				1				1	1
Skin and subcutaneous tissue disorders									1
Skin hyperpigmentation		1						1	1
Other (local infection				1				1	1
Blood and lymphatic system disorders		_							
Lymph rode pain				1				1	1
Reproductive system and breast disorders									
Pregnancy				1				1	1
Dislocation of hip, baby						1		1	1
Total	11	26	4	10		1	15	37	52
display the preprint in perpetuity.	R	NR	R	NR	R	NR	R	NR	R+NF
Fever	1	-	1				2		2
Flu like symfoms		2						2	2
Pain/redness at sile	2	_		_		_	2		2
Nervous system disorders							2		
Headache Musculoskeletal and connecity lissue dissorders	2				-		2		2
	1	1	-	-		-	1	1	2
Muscle (body) pain	1	1	-				1	1	1
Gastro-intestinal disorders		-	-	0			_		2
Toolhache		_	-	2			_	2	
Nausea/vomiting		_		1	-			1	1
Upper respiratory intections	2	2	1	1			3	3	6
	~	2	1			-	3	-	
Vaginal Infection		_	-	1		_		1	1
Blood and lymphatic system disorders									
Lymph node pain	9	5	2	5			1	10	21
Total			*	0				10	21
Total							-	da.l	Total
Total Cohort D			14.4		0.			tal	Tota R+NF
		NR	Mod	erate NR	Ser R	NR	R	NR	
Cohort D System organ class & AE General disorders and administrative site conditions	м			NR					
Cohort D System organ class & AE General disorders and administrative site conditions Fiu like symtoms	R						R	1	1
Cohort D System organ class & AE General disorders and administrative site conditions	м			NR					1
Cohort D System organ class & AE General disorders and administrative site conditions Fiu like symtoms	R			NR			R		
Cohort D System organ class & AE General disorders and administrative site conditions Fullike symtoms Pain/redness at site	R			NR			R		
Cohort D System organ class & AE General disorders and administrative site conditions Fu like symtoms Pain/redness at site Nervous system disorders	R 3	NR		NR			8 3	1	3
Cohort D System organ class & AE General disorders and administrative site conditions Fu like symtoms Pain/indness at site Nervous system disorders Headache	R 3	NR		NR			8 3	1	3
Cohort D System organ class & AE General disorders and administrative site conditions Flu like symtoms Pain/redness at site Nervous system disorders Headache Dizziness	R 3	NR		NR			8 3	1	3
Cohort D System organ class & AE General disorders and administrative site conditions Flu like symtoms Pain/redness at site Nervous system disorders Headache Dizziness Musculoskeletal and connectly tissue dissorders	8 3 4	NR	R	NR			R 3 4	1	3
Cohort D System organ class & AE General disorders and administrative site conditions Fullike symtoms Pain/redness at site Nervous system disorders Headache Dizziness Musculoskeletal and connectiv tissue dissorders Musce (body) pain	8 3 4	NR 1	R	NR			R 3 4	1	3 5 2
Cohort D System organ class & AE General disorders and administrative site conditions Fullie symtoms Pain/redness at site Nervous system disorders Headache Dizziness Muscle (body) pain Back pain Gastro-intestinal disorders	8 3 4	NR 1	R	NR 1			R 3 4	1	3 5 2 2 2
Cohort D System organ class & AE General disorders and administrative site conditions Fulke symioms Pain/redness at site Nervous system disorders Headache Dizziness Musculoskeletal and connectiv tissue disorders Musculoskeletal and connectiv tissue disorders M	8 3 4	NR 1	R	NR			R 3 4	1	3 5 2 2 2 2
Cohort D System organ class & AE General disorders and administrative site conditions Flu like symtoms Pain/redness at site Nervous system disorders Headache Dizziness Musculoskeletal and connectly tissue dissorders Musck (body) pain Back pain Gastro-Intestinal disorders Other (Stomach flu Diambea	8 3 4	NR 1	R	NR 1			R 3 4	1 1 2 2	3 5 2 2 2
Cohort D System organ class & AE General disorders and administrative site conditions Fulles syntoms Pain/redness at site Nervous system disorders Headache Dizziness Musceloekkeletal and connectly tissue dissorders Musce (body) pain Back pain Gastro-intestinal disorders Other (Stomach flu Diambea Intections and intestations	8 3 4	NR 1	R	NR 1			R 3 4	1 1 2 2	3 5 2 2 2 2
Cohort D System organ class & AE General disorders and administrative site conditions Pulike symtoms Pain/redness at site Nervous system disorders Headache Dizziness Musculoskeletal and connectly lissue dissorders Musck (pody) pain Back pain Gastro-intestinal disorders Other (Stomach flu Diamhea Infections and Infestations Upper respiratory intection (tórkyining)	M R 3 4	NR 1	R	NR 1 2 1			R 3 4 2	1 1 2 2 1	3 5 2 2 2 1
Cohort D System organ class & AE General disorders and administrative site conditions Fulles syntoms Pain/redness at site Nervous system disorders Headache Dizziness Musceloekkeletal and connectly tissue dissorders Musce (body) pain Back pain Gastro-intestinal disorders Other (Stomach flu Diambea Intections and intestations	M R 3 4	NR 1	R	NR 1 2 1			R 3 4 2	1 1 2 2 1	3 5 2 2 2 1

Cohort E


Andrew service all all	N	6id	Mod	erate	Se	vere	To	otal	Total
System organ class & AE	R	NR	R	NR	R	NR	R	NR	R+NP
General disorders and administrative site conditions									
Pain/redness at sile	2						2		2
Musculoskeletal and connecity tissue dissorders									
Muscle (body) pain		1						1	1
Back pain		1						1	1
Gastro-Intestinal disorders									
Toothache		1						1	1
Other (Stomach flu			1				1		1
Nausea/vomiting		1						1	1
Infections and infestations									
Upper respiratory infection (förkylning)		8		1				9	9
Respiratory, thoracic and mediastinal disorders									
Sore throat		1						1	1
Cough		1						1	1
Preumonitie						1		1	1
Total	2	14	,	1		1	3	16	19

	A1	A2	B1	B2	с	D	E	Totalt
	(n=23)	(n=20)	(n=21)	(n=21)	(n=20)	(n=20)	(n=20)	(n=145)
Total AE	42	52	26	21	37	31	19	228
Donors with at least one AE	19	16	12	10	16	16	11	100
Severity:								
Mild	37	36	22	14	27	25	16	177
Moderate	4	15	4	7	9	6	2	47
Severe	1	1	0	0	1	0	1	4
Related to vaccination								
Unlikely	25	37	19	10	21	20	16	148
Possible	8	3	2	8	6	1	2	30
Probable	9	12	5	3	10	10	1	50
Related total	17	15	7	11	16	11	3	80

Supplementary Table 2 | Summary of registered adverse events




S1 Fig. Soluble cytokine concentrations in serum following vaccination. (A) Heat map of fold changes of all detectable soluble factors in serum following vaccination. (B) Box and whisker plots comparing serum TNF and IL-18 concentrations following the first vaccine dose. The legend denotes color-coding of the seven cohorts. Statistical analyses were performed using nonparametric Friedman and Kruskal-Wallis test with Dunn's multiple comparison tests.



S2 Fig. Sex-based comparisons of final virus nAb titers. (A) Comparisons of male (M) vs female (F) TBEV nAb titers at the final time point in cohort A1 and A2 (left panel), cohort C (middle panel) and combined A and C cohorts (right panel). (B) Comparisons of male (M) vs female (F) JEV nAb titers at the final time point in cohort B1 and B2 (left panel), cohort D (middle panel) and combined B and D cohorts (right panel). (C) Comparisons of male (M) vs female (F) YFV nAb titers at the final time point in cohort E (left panel) and combined A, B, and E cohorts (right panel). The legend denotes color-coding of the seven cohorts. Statistical analyses

were performed using nonparametric Friedman and Kruskal-Wallis test with Dunn's multiple

comparison tests. *p < 0.05.



S3 Fig. Immunoglobulin expression of circulating plasmablasts. (A) Median IgG expression of plasmablasts over time following vaccination and comparison of peak expression between cohorts at days (B) 14, (C) 37 and (D) 187. (E) Median IgA expression of plasmablasts over time following vaccination and (F) comparison of lowest expression between cohorts at day14. (G) Median IgG-A- expression of plasmablasts over time following vaccination and (H) comparison

of peak expression between cohorts at day14. The legend denotes color-coding of the seven

cohorts. All plots are depicted with median values with IQR. Statistical analyses were performed

using nonparametric Kruskal-Wallis test with Dunn's multiple comparison tests. *p < 0.05, **p <

0.01, ***p < 0.001.